Net Income (Loss) Attributable to Parent of Galmed Pharmaceuticals Ltd. from 31 Dec 2019 to 30 Sep 2025

Taxonomy & unit
us-gaap: USD
Description
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
Summary
Galmed Pharmaceuticals Ltd. quarterly and annual Net Income (Loss) Attributable to Parent in USD history and change rate from 31 Dec 2019 to 30 Sep 2025.
  • Galmed Pharmaceuticals Ltd. Net Income (Loss) Attributable to Parent for the quarter ending 30 Sep 2025 was $1,892,000, a 1.1% increase year-over-year.
  • Galmed Pharmaceuticals Ltd. Net Income (Loss) Attributable to Parent for the twelve months ending 30 Sep 2025 was $8,700,000.
  • Galmed Pharmaceuticals Ltd. annual Net Income (Loss) Attributable to Parent for 2024 was $7,517,000, a 8.8% decline from 2023.
  • Galmed Pharmaceuticals Ltd. annual Net Income (Loss) Attributable to Parent for 2023 was $6,912,000, a 61% increase from 2022.
  • Galmed Pharmaceuticals Ltd. annual Net Income (Loss) Attributable to Parent for 2022 was $17,866,000, a 45% increase from 2021.
Source SEC data
View on sec.gov
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Quarterly (USD)
Net Income (Loss) Attributable to Parent, YoY Quarterly Change (%)
Net Income (Loss) Attributable to Parent, Annual (USD)
Net Income (Loss) Attributable to Parent, YoY Annual Change (%)

Galmed Pharmaceuticals Ltd. Quarterly Net Income (Loss) Attributable to Parent (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q3 2025 $8,700,000 $1,892,000 +$22,000 +1.1% 01 Jul 2025 30 Sep 2025 6-K 26 Nov 2025 2025 Q3
Q2 2025 $8,722,000 $2,495,000 -$1,376,000 -123% 01 Apr 2025 30 Jun 2025 6-K 28 Aug 2025 2025 Q2
Q1 2025 $7,346,000 $1,104,000 +$171,000 +13% 01 Jan 2025 31 Mar 2025 6-K 28 Aug 2025 2025 Q2
Q4 2024 $7,517,000 $3,209,000 01 Oct 2024 31 Dec 2024 20-F 02 Apr 2025 2024 FY
Q3 2024 $1,914,000 01 Jul 2024 30 Sep 2024 6-K 26 Nov 2025 2025 Q3
Q2 2024 $1,119,000 +$474,000 +30% 01 Apr 2024 30 Jun 2024 6-K 28 Aug 2025 2025 Q2
Q1 2024 $1,275,000 +$555,000 +30% 01 Jan 2024 31 Mar 2024 6-K 28 Aug 2025 2025 Q2
Q2 2023 $1,593,000 +$2,141,000 +57% 01 Apr 2023 30 Jun 2023 6-K 28 Aug 2024 2024 Q2
Q1 2023 $1,830,000 +$4,313,000 +70% 01 Jan 2023 31 Mar 2023 6-K 28 Aug 2024 2024 Q2
Q2 2022 $3,734,000 +$4,662,000 +56% 01 Apr 2022 30 Jun 2022 6-K 09 Aug 2023 2023 Q2
Q1 2022 $6,143,000 +$2,762,000 +31% 01 Jan 2022 31 Mar 2022 6-K 09 Aug 2023 2023 Q2
Q2 2021 $8,396,000 -$2,870,000 -52% 01 Apr 2021 30 Jun 2021 6-K 04 Aug 2022 2022 Q2
Q1 2021 $8,905,000 -$2,842,000 -47% 01 Jan 2021 31 Mar 2021 6-K 04 Aug 2022 2022 Q2
Q2 2020 $5,526,000 01 Apr 2020 30 Jun 2020 6-K 05 Aug 2021 2021 Q2
Q1 2020 $6,063,000 01 Jan 2020 31 Mar 2020 6-K 05 Aug 2021 2021 Q2

Galmed Pharmaceuticals Ltd. Annual Net Income (Loss) Attributable to Parent (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2024 $7,517,000 -$605,000 -8.8% 01 Jan 2024 31 Dec 2024 20-F 02 Apr 2025 2024 FY
2023 $6,912,000 +$10,954,000 +61% 01 Jan 2023 31 Dec 2023 20-F 02 Apr 2025 2024 FY
2022 $17,866,000 +$14,601,000 +45% 01 Jan 2022 31 Dec 2022 20-F 02 Apr 2025 2024 FY
2021 $32,467,000 -$3,696,000 -13% 01 Jan 2021 31 Dec 2021 20-F 04 Apr 2024 2023 FY
2020 $28,771,000 -$8,310,000 -41% 01 Jan 2020 31 Dec 2020 20-F 29 Mar 2023 2022 FY
2019 $20,461,000 01 Jan 2019 31 Dec 2019 20-F 02 May 2022 2021 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.